• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

58.02 UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
August 30, 2023
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
August 11, 2023
Company maintains strong cash position of $205 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023 ↗
August 09, 2023
 
Via Benzinga
News headline image
The Latest Analyst Ratings for RAPT Therapeutics ↗
August 09, 2023
 
Via Benzinga
News headline image
Analyst Ratings for RAPT Therapeutics ↗
June 05, 2023
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗
June 15, 2023
 
Via Benzinga
News headline image
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
June 07, 2023
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
May 25, 2023
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations for RAPT Therapeutics's Future ↗
May 12, 2023
 
Via Benzinga
News headline image
Recap: RAPT Therapeutics Q1 Earnings ↗
May 11, 2023
 
Via Benzinga
News headline image
The Latest Analyst Ratings for RAPT Therapeutics ↗
March 15, 2023
 
Via Benzinga
News headline image
RAPT Therapeutics Reports First Quarter 2023 Financial Results
May 11, 2023
Company maintains strong cash position of $231.6 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
May 03, 2023
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From RAPT Therapeutics, Inc.
Via GlobeNewswire
What 5 Analyst Ratings Have To Say About RAPT Therapeutics ↗
January 04, 2023
 
Via Benzinga
News headline image
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
April 17, 2023
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82. 
Via Benzinga
News headline image
Why Marpai Shares Are Trading Lower By 26%; Here Are 20 Stocks Moving Premarket ↗
April 17, 2023
Gainers CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) jumped 153% to $5.96 in pre-market trading after jumping 243% on Friday. 
Via Benzinga
News headline image
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
April 17, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93... 
Via Benzinga
News headline image
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
March 29, 2023
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
News headline image
S&P 500 Rises 1%; Crude Oil Down Over 4% ↗
March 14, 2023
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 1.5% on Tuesday. The Dow traded up 0.40% to 31,945.39 while the NASDAQ rose 1.58% to 11,365.53. The S&P 500,... 
Via Benzinga
News headline image
Dow Extends Rebound, Surges 456 Points ↗
March 14, 2023
Rallying bank stocks are fueling Wall Street's midday gains, as investors continue to unpack this morning's consumer price index (CPI) data. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
March 14, 2023
 
Via Benzinga
News headline image
Nasdaq Jumps Over 200 Points; GitLab Shares Plummet ↗
March 14, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 400 points on Tuesday. The Dow traded up 1.30% to 32,234.35 while the NASDAQ rose 2.07% to 11,421.23. The S&P 500,... 
Via Benzinga
News headline image
Dow Surges Over 300 Points; US Inflation Rate Drops To 6% ↗
March 14, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded up 1.03% to 32,145.42 while the NASDAQ rose... 
Via Benzinga
News headline image
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
March 14, 2023
Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a... 
Via Benzinga
News headline image
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
March 14, 2023
Company maintains strong cash position of $249.1 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 07, 2023
From RAPT Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session ↗
January 13, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023 ↗
January 04, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap